Prime Medicine Inc (PRME) Stock Analysis
Verdict: HOLD
Technological leadership in prime editing is currently overshadowed by a critical 6-month cash runway and a consistent track record of earnings misses.
Investment score: 44/100
Analysis as of
Is Prime Medicine Inc stock worth reviewing? AI model thesis
Prime Medicine offers high-upside gene-editing tech but faces severe liquidity constraints and valuation disconnects compared to peers.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 60/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Prime Medicine Inc opportunities and risks
What speaks for PRME
- Prime Editing Differentiation
What speaks against PRME
- Imminent Liquidity Crisis / Dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PRME | n/a | 165.2x | n/a | -1082.7% | -4917.6% | -23.8% |
| EIKN | n/a | 0.0x | n/a | 0.0% | 0.0% | -342.4% |
| TRAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.1% |
| FDMT | n/a | 7.9x | n/a | -12.4% | -182.3% | -18.7% |
| IRWD | 6.6x | 1.9x | 5.2x | 99.6% | 28.3% | 16.2% |
| ACHV | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.8% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.1% |
Frequently asked questions about Prime Medicine Inc (PRME)
Is PRME stock a good investment?
The cached TradeMates AI model rates Prime Medicine Inc as HOLD with an investment score of 44/100. Prime Medicine offers high-upside gene-editing tech but faces severe liquidity constraints and valuation disconnects compared to peers. This is algorithmic model output, not personal investment advice.
Is PRME stock a buy?
The TradeMates model verdict for PRME is HOLD with an investment score of 44/100. Treat this as a model signal to review, not a personal buy recommendation.